These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2620051)

  • 1. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma.
    Hawkins RE; Roberts K; Wiltshaw E; Mundy J; Fryatt IJ; McCready VR
    Br J Obstet Gynaecol; 1989 Dec; 96(12):1395-9. PubMed ID: 2620051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
    Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
    Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 125 half-life in ovarian cancer: a multivariate survival analysis.
    Yedema CA; Kenemans P; Voorhorst F; Bon G; Schijf C; Beex L; Verstraeten A; Hilgers J; Vermorken J
    Br J Cancer; 1993 Jun; 67(6):1361-7. PubMed ID: 8512822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma.
    Högberg T; Kågedal B
    Acta Obstet Gynecol Scand; 1990; 69(5):423-9. PubMed ID: 2270768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA-125 in ovarian cancer: relation between half-life, doubling time and survival.
    Willemse PH; Aalders JG; de Bruyn HW; Mulder NH; Sleijfer DT; de Vries EG
    Eur J Cancer; 1991; 27(8):993-5. PubMed ID: 1832911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
    Markowska J; Kopczyński Z; Manyś G; Szewierski Z
    Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
    Hunter VJ; Daly L; Helms M; Soper JT; Berchuck A; Clarke-Pearson DL; Bast RC
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1164-7. PubMed ID: 2171337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic indicators for poor risk epithelial ovarian carcinoma.
    Rosman M; Hayden CL; Thiel RP; Chambers JT; Kohorn EI; Chambers SK; Schwartz PE
    Cancer; 1994 Aug; 74(4):1323-8. PubMed ID: 8055455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 125 in monitoring chemotherapy of the patients with ovarian cancer.
    Markowska J; Kojczynski Z; Szewierski Z; Manys G
    Eur J Gynaecol Oncol; 1990; 11(3):209-14. PubMed ID: 2209640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
    Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.
    van der Burg ME; Lammes FB; van Putten WL; Stoter G
    Gynecol Oncol; 1988 Jul; 30(3):307-12. PubMed ID: 3164697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic significance of the CA 125 half-life for the further outcome of ovarian cancer].
    Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
    Geburtshilfe Frauenheilkd; 1992 Sep; 52(9):526-32. PubMed ID: 1397953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer.
    Sevelda P; Schemper M; Spona J
    Am J Obstet Gynecol; 1989 Nov; 161(5):1213-6. PubMed ID: 2589442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary.
    Davidson NG; Khanna S; Kirwan PH; Bircumshaw D
    Clin Oncol (R Coll Radiol); 1991 Jan; 3(1):32-6. PubMed ID: 2001340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.